Ionotropic Glutamate Receptors and Expression of N-Methyl-d-Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Multiple quantifiable biologic abnormalities have been localized to the hippocampus in schizophrenia. Alterations in glutamate-mediated transmission at N-methyl-D-aspartic acid (NMDA)-sensitive receptors in hippocampus have been implicated in the pathophysiology of the illness. The authors tested the hypothesis that glutamatergic transmission within and efferent from hippocampus is altered in schizophrenia. METHOD: The authors analyzed postmortem hippocampal tissue from individuals with schizophrenia and from healthy individuals. The tissue samples had been collected by two brain tissue banks, one in Maryland and the other in Melbourne, Australia. lonotropic receptor binding for the NMDA, kainate, and (3)H-amino-3-hydroxy-5-methylisoxazol-4-propionate (AMPA) receptors was quantified by using usual radioligand techniques. In situ hybridization autoradiography was used to quantify mRNA for the NMDA receptor subunits NR1, NR2A, and NR2B. RESULTS: Ligand binding to the ionotropic glutamate receptors (NMDA, kainate, and AMPA) did not differ significantly overall or in any subregion between the schizophrenia tissue and the healthy comparison tissue. The only exception was AMPA receptor binding in hippocampal subregion CA2, which was slightly but significantly less in schizophrenia. However, the level of mRNA for the NMDA receptor subunits NR1 and NR2B was significantly different between groups; in several hippocampal subregions, the level of NR1 mRNA was lower and the level of NR2B mRNA higher in schizophrenia. CONCLUSIONS: Because the NR1 subunit of the NMDA receptor is critical to full receptor activity, a reduction of NR1 in hippocampus in schizophrenia suggests a functional impairment in glutamatergic transmission at the NMDA receptor, resulting in reduced glutamatergic transmission within and possibly efferent from the hippocampus in schizophrenia. This defect could underlie a hypoglutamatergic state in regions of limbic cortex, consistent with published results from other lines of research in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Subregion- and Cell Type–Restricted Gene Knockout in Mouse Brain
Tsien, J. Z., Chen, D. F., Gerber, D., Tom, C., Mercer, E. H., Anderson, D. J., Mayford, M., Kandel, E. R., & Tonegawa, S. (1996) · Cell · doi:10.1016/s0092-8674(00)81826-7 · Cited by 1,280
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Stevens, J. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.04200020023003 · Cited by 722
Impaired Hippocampal Representation of Space in CA1-Specific NMDAR1 Knockout Mice
McHugh, T. J., Blum, K. I., Tsien, J. Z., Tonegawa, S., & Wilson, M. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81828-0 · Cited by 593
Cited by
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Harrison, P. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1761-y · Cited by 693
“…glutamate receptors (Kerwin et al. 1988, 1990; Harrison et al. 1991; Eastwood et al. 1995b, 1997a, 1997b; Porter et al. 1997; Dean et al. 1999; Gao et al. 2000; Law and Deakin 2001) and other glutamatergic indices (Tsai et al. 1995), GABA receptors and uptake sites (Reynolds et al. 1990;…”
BackgroundIncreased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Self-citationThe Hippocampal Formation in Schizophrenia
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 582
Self-citationGlutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Roceri, M., Hendriks, W., Racagni, G., Ellenbroek, B. A., & Riva, M. A. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001036 · Cited by 464
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
Phillips, W. A., & Silverstein, S. M. (2003) · Behavioral and Brain Sciences · doi:10.1017/s0140525x03000025 · Cited by 445
“Furthermore, a recent study of post-mortem hippocampal tissue suggests that it may not be the number of NMDA-channels that is pathological, but their subunit composition (Gao et al. 2000).”
BackgroundHof, P. R., Haroutunian, V., Friedrich, V. L., Byne, W., Buitron, C., Perl, D. P., & Davis, K. L. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00237-3 · Cited by 433
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Lieberman, J. A., Girgis, R. R., Brucato, G., Moore, H., Provenzano, F., Kegeles, L., Javitt, D., Kantrowitz, J., Wall, M. M., Corcoran, C. M., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.249 · Cited by 376
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Loftis, J. M., & Janowsky, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00302-9 · Cited by 362
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
“Several investigators have reported that the expression of AMPA and kainate receptor subtypes is reduced in the hippocampus, an area that is thought to play an important role in schizophrenia (Gao et al., 2000; Meador-Woodruff & Healy, 2000).”
BackgroundRediscovering area CA2: unique properties and functions
Dudek, S. M., Alexander, G. M., & Farris, S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.22 · Cited by 330
A Review of the Fetal Brain Cytokine Imbalance Hypothesis of Schizophrenia
Meyer, U., Feldon, J., & Yee, B. K. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn022 · Cited by 320
Bussey, T. J., Holmes, A., Lyon, L., Mar, A. C., McAllister, K. A. L., Nithianantharajah, J., Oomen, C. A., & Saksida, L. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.011 · Cited by 299
Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Vawter, M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00377-2 · Cited by 275
Phenotype of schizophrenia: a review and formulation
Tamminga, C. A., & Holcomb, H. H. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001563 · Cited by 262
Self-citationProbing the human hippocampus using rCBF: Contrasts in schizophrenia
Medoff, D. R., Holcomb, H. H., Lahti, A. C., & Tamminga, C. A. (2001) · Hippocampus · doi:10.1002/hipo.1070 · Cited by 257
Self-citationTarabeux, J., Kebir, O., Gauthier, J., Hamdan, F. F., Xiong, L., Piton, A., Spiegelman, D., Henrion, É., Millet, B., S2D team, et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.52 · Cited by 231
Kristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“For example, the depressed NR1 expression and elevated NR2B expression observed in schizophrenia (Gao et al. 2000) may interfere with the pruning process in a variety of ways, by resulting in hypofunction of NMDAR-mediated neurotransmission, or excitotoxicity or the potentiation of inappropriate synapses due to increa…”
BackgroundMishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156
The glutathione cycle shapes synaptic glutamate activity
Sedlak, T. W., Paul, B. D., Parker, G. M., Hester, L. D., Snowman, A. M., Taniguchi, Y., Kamiya, A., Snyder, S. H., & Sawa, A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817885116 · Cited by 147
Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms
Satterthwaite, T. D., Wolf, D. H., Calkins, M. E., Vandekar, S. N., Erus, G., Ruparel, K., Roalf, D. R., Linn, K. A., Elliott, M. A., Moore, T. M., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3463 · Cited by 132
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Nakazawa, K., Jeevakumar, V., & Nakao, K. (2017) · npj Schizophrenia · doi:10.1038/s41537-016-0003-3 · Cited by 110
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89
The role of P2X7 receptors in a rodent PCP-induced schizophrenia model
Koványi, B., Csölle, C., Calovi, S., Hanuska, A., Kató, E., Köles, L., Bhattacharya, A., Haller, J., & Sperlágh, B. (2016) · Scientific Reports · doi:10.1038/srep36680 · Cited by 52
“These data are consistent with the elevation of NR2B protein expression to acute PCP treatment in the frontal cortex of the rat brain 38 , and with human post mortem studies, founding increased NR2B subunit mRNA and protein levels in cortical areas of schizophrenic patients 27,39,40 , but see ref.”
Takase, K., Yamamoto, Y., & Yagami, T. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.016 · Cited by 40
André, J. M., Leach, P. T., & Gould, T. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.004 · Cited by 32
Metadata
- Authors
- Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A.
- Venue
- American Journal of Psychiatry
- Published
- 2000-07-01
- Volume
- 157
- Issue
- 7
- Pages
- 1141-1149
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2143417330
- Cited by
- 372
- References
- 64
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.